Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|October 25, 2024

Uncertainty With Artificial Intelligence at the Site-Level

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses challenges and trends he is currently hearing about from sites.

In a recent video interview with Applied Clinical Trials, Jimmy Bechtel, vice president, site engagement, SCRS, discussed key challenges and initiatives at the site-level. AI's impact on sites is significant, with uncertainty around its implementation. Diversity requirements pose challenges, and technology overload is a major issue due to inconsistent tech stacks and financial burdens on sites. Bechtel also highlighted some initiatives that SCRS is currently working on and gave an overview of the most recent Global Site Solutions Summit.

A transcript of Bechtel’s conversation with ACT can be found below.

ACT: What are some current challenges or trends for sites that you’ve been hearing about recently?

Bechtel: AI (artificial intelligence) is definitely the new hot topic for the sites. It's not necessarily a challenge right now, there's a lot of unknowns, and sites don't want it to become a challenge and things like this tend to become a challenge. They happen at the sponsor, CRO, and service provider levels, and then the sites suffer the ramifications of whatever decisions are made at the industry level, so that that's definitely one that the sites have a big question mark around and there's a lot of discussion, a lot of thirst for information, and how is this being used? How can I use it as a site, etc.?

Then diversity, I think, is also a big challenge at the site level, knowing how to meet the needs. Even farther back from that, what the needs are going to be, what are sponsors and CROs going to be asking of sites with diversity plans and things like that? How can they be prepared to meet those? Should they be presented with some sort of diversity-level requirement—an inclusive-level requirement on their clinical trials?


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.